Target Price | $491.13 |
Price | $414.73 |
Potential |
18.42%
register free of charge
|
Number of Estimates | 15 |
15 Analysts have issued a price target United Therapeutics Corporation 2026 .
The average United Therapeutics Corporation target price is $491.13.
This is
18.42%
register free of charge
$603.75
45.58%
register free of charge
$324.02
21.87%
register free of charge
|
|
A rating was issued by 21 analysts: 14 Analysts recommend United Therapeutics Corporation to buy, 7 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the United Therapeutics Corporation stock has an average upside potential 2026 of
18.42%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Billion $ | 2.88 | 3.27 |
23.63% | 13.71% | |
EBITDA Margin | 52.85% | 52.38% |
0.94% | 0.88% | |
Net Margin | 41.53% | 38.29% |
1.84% | 7.81% |
16 Analysts have issued a sales forecast United Therapeutics Corporation 2025 . The average United Therapeutics Corporation sales estimate is
This results in the following potential growth metrics:
9 Analysts have issued an United Therapeutics Corporation EBITDA forecast 2025. The average United Therapeutics Corporation EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
17 United Therapeutics Corporation Analysts have issued a net profit forecast 2025. The average United Therapeutics Corporation net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | 24.64 | 27.70 |
24.38% | 12.42% | |
P/E | 14.97 | |
EV/Sales | 4.80 |
17 Analysts have issued a United Therapeutics Corporation forecast for earnings per share. The average United Therapeutics Corporation EPS is
This results in the following potential growth metrics and future valuations:
United Therapeutics Corporation...
Analyst | Rating | Action | Date |
---|---|---|---|
Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Sep 10 2025 |
Oppenheimer |
Locked
➜
Locked
|
Locked | Sep 05 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 05 2025 |
UBS |
Locked
➜
Locked
|
Locked | Sep 04 2025 |
Wells Fargo |
Locked
➜
Locked
|
Locked | Sep 03 2025 |
Jefferies |
Locked
➜
Locked
|
Locked | Sep 02 2025 |
B of A Securities |
Locked
➜
Locked
|
Locked | Sep 02 2025 |
Analyst Rating | Date |
---|---|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Sep 10 2025 |
Locked
Oppenheimer:
Locked
➜
Locked
|
Sep 05 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 05 2025 |
Locked
UBS:
Locked
➜
Locked
|
Sep 04 2025 |
Locked
Wells Fargo:
Locked
➜
Locked
|
Sep 03 2025 |
Locked
Jefferies:
Locked
➜
Locked
|
Sep 02 2025 |
Locked
B of A Securities:
Locked
➜
Locked
|
Sep 02 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.